Printer Friendly

SYNTEX EXTENDS DISCOUNTED PRICES TO FEDERALLY FUNDED PUBLIC HEALTH SERVICE CENTERS

 SYNTEX EXTENDS DISCOUNTED PRICES TO FEDERALLY FUNDED
 PUBLIC HEALTH SERVICE CENTERS
 PALO ALTO, Calif., Jan. 23 /PRNewswire/ -- Syntex Corp. (NYSE: SYN) announced today that the company is voluntarily extending discounted prices on its prescription medicines to nonprofit health centers that are federally funded by the United States Public Health Service and qualify for the Syntex program.
 Effective April 1, 1992, discounts comparable to the 12.5 percent minimum rebate provided to the Medicaid program will be extended to eligible federally funded Public Health Service clinics that treat the poor, uninsured or otherwise medically underserved people, when these eligible centers purchase Syntex medicines directly or via Syntex-approved Prime Vendor arrangements with pharmaceutical wholesalers.
 Syntex currently provides rebates to the Medicaid program under the provisions of the federal Omnibus Budget Reconciliation Act passed in October 1990. Many patients treated by Public Health Service-funded centers are ineligible for Medicaid assistance.
 "We want to be part of the solution to providing the poor with access to prescription medicines," Syntex Chairman and Chief Executive Officer Paul E. Freiman said. "Prevention and early treatment with prescription pharmaceuticals is a sure-fire way of controlling healthcare costs. We hope, in this way, to help lighten the federal government's burden in paying for healthcare for the poor," he said.
 Syntex said similar discounts will be extended to all eligible federally funded non-Public Health Service clinics that agree to make all of the company's prescription medicines available to their patients.
 Syntex will be working out final details of the program in the coming weeks.
 Syntex is a multinational healthcare company that discovers, develops, manufactures and markets prescription medicines that treat serious human diseases. Syntex also develops, manufactures and markets animal pharmaceutical products and medical diagnostic systems.
 -0- 1/23/92
 /CONTACT: Linda Thomas, 415-852-1321; or Kathleen Gary, 415-855-5924/
 (SYN) CO: Syntex Corp. ST: California IN: MTC SU: PDT


RM -- SJ004 -- 2836 01/23/92 13:11 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 23, 1992
Words:317
Previous Article:LAFARGE CORPORATION REPORTS 1991 LOSS
Next Article:MID-STATE FEDERAL ANNOUNCES FIRST QUARTER RESULTS
Topics:


Related Articles
BRISTOL-MYERS SQUIBB ANNOUNCES VOLUNTARY REDUCTION IN PHARMACEUTICAL PRICES TO FEDERAL GOVERNMENT
ASTRA TO SUPPORT KENNEDY FEDERAL DRUG PRICE REBATE LEGISLATION; TO DEVELOP VOLUNTARY DISCOUNT PROGRAM ON NEW AIDS DRUG, OTHER PRODUCTS
SEARLE ANNOUNCES SPECIFICS OF DISCOUNT PRICING TO PUBLIC HEALTH SERVICE CLINICS
GLAXO TO OFFER PRICE DISCOUNTS TO PUBLIC HEALTH CLINICS
PFIZER ANNOUNCES SUPPORT FOR KENNEDY/HATCH BILL THAT WOULD PROVIDE DRUG DISCOUNTS TO PUBLIC HEALTH CLINICS
BURROUGHS WELLCOME VOLUNTARILY REDUCES PRESCRIPTION DRUG PRICES TO FEDERALLY FUNDED PUBLIC HEALTH CLINICS AND GOVERNMENT AGENCIES USING FSS
SANDOZ ANNOUNCES PRICE REDUCTION TO VETERANS ADMINISTRATION, PUBLIC HEALTH SERVICE AND OTHER FEDERAL CLINICS
ASTRA CUTS FOSCAVIR PRICE FOR AIDS PATIENTS IN FEDERALLY FUNDED PROGRAMS
Summer price spike: a case study about publicly funded clinics and the cost of contraceptive supplies.
Pharmaceutical savings.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters